title: Molecular investigation of secondary chronic myeloid leukemia.
authors.forename: R C
authors.initials: RC
authors.lastname: Aguiar
authors.forename: H
authors.initials: H
authors.lastname: Sill
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
authors.forename: J M
authors.initials: JM
authors.lastname: Goldman
authors.forename: N C
authors.initials: NC
authors.lastname: Cross
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D003131:Combined Modality Therapy / Q000009:adverse effects; D004273:DNA, Neoplasm; D016147:Genes, Tumor Suppressor; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000209:etiology / Q000235:genetics*; D008297:Male; D016609:Neoplasms, Second Primary / Q000235:genetics*; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011878:Radiotherapy / Q000009:adverse effects; D018239:Seminoma / Q000628:therapy; D013736:Testicular Neoplasms / Q000628:therapy; D013945:Thymoma / Q000628:therapy; D013953:Thymus Neoplasms / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm